Camilla Simpson

Head of Product Portfolio Development at BioMarin Pharmaceutical, Inc.

Camilla Simpson

Camilla Simpson

Head of Product Portfolio Development at BioMarin Pharmaceutical, Inc.

Overview
RelSci Relationships

337

Number of Boards

1

Contact Data
Trying to get in touch with Camilla Simpson? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Camilla Simpson likely has professional access to. A relationship does not necessarily indicate a personal connection.

Venture Partner at Pappas Capital LLC

Relationship likelihood: Strong

Chief Executive Officer & President at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Strong

Executive Vice President, General Counsel & Secretary at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Strong

Senior Partner at Novo Ventures (US), Inc.

Relationship likelihood: Strong

Co-Founder at Mirum Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Spruce Biosciences, Inc.

Relationship likelihood: Strong

Chief Financial Officer & Executive Vice President at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Executive Director at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Executive Director at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Executive Vice President & Chief Commercial Officer at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Paths to Camilla Simpson
Potential Connections via
Relationship Science
You
Camilla Simpson
Head of Product Portfolio Development at BioMarin Pharmaceutical, Inc.
Career History
Head of Product Portfolio Development
Tenure Unconfirmed

About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

Other Affiliations

Camilla Simpson is affiliated with BioMarin Pharmaceutical, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Camilla Simpson. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Camilla Simpson's profile does not indicate a business or promotional relationship of any kind between RelSci and Camilla Simpson.